Summary
Global Markets Direct’s, ‘Colitis - Pipeline Review, H2 2016’, provides an overview of the Colitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colitis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Colitis
- The report reviews pipeline therapeutics for Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Colitis therapeutics and enlists all their major and minor projects
- The report assesses Colitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Colitis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Colitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Colitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Aerpio Therapeutics, Inc.
Akebia Therapeutics, Inc.
Amorepacific Corporation
Bayer AG
Bristol-Myers Squibb Company
Cosmo Pharmaceuticals S.p.A
Dr. Falk Pharma GmbH
EA Pharma Co Ltd
Euroscreen S.A.
Genfit SA
Immuron Limited
Innate Pharma S.A.
Peptinov SAS
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Colitis Overview 10
Therapeutics Development 11
Pipeline Products for Colitis - Overview 11
Pipeline Products for Colitis - Comparative Analysis 12
Colitis - Therapeutics under Development by Companies 13
Colitis - Therapeutics under Investigation by Universities/Institutes 15
Colitis - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Colitis - Products under Development by Companies 19
Colitis - Products under Investigation by Universities/Institutes 20
Colitis - Companies Involved in Therapeutics Development 21
Aerpio Therapeutics, Inc. 21
Akebia Therapeutics, Inc. 22
Amorepacific Corporation 23
Bayer AG 24
Bristol-Myers Squibb Company 25
Cosmo Pharmaceuticals S.p.A 26
Dr. Falk Pharma GmbH 27
EA Pharma Co Ltd 28
Euroscreen S.A. 29
Genfit SA 30
Immuron Limited 31
Innate Pharma S.A. 32
Peptinov SAS 33
Pfizer Inc. 34
Prokarium Limited 35
RDD Pharma Ltd. 36
Saniona AB 37
Synovo GmbH 38
Colitis - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
AcTMP-1 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
AKB-4924 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
AKB-6899 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
AN-346 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Antibody for Colitis - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
APY-0201 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
BC-1215 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
BMS-986104 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
budesonide - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Clostridium difficile vaccine - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
CSY-0073 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
elafibranor - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
ESN-601 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
IMM-124E - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
IPH-33 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
mesalamine - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
NK-007 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
PAC-14028 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
PF-06425090 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
PPV-06 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
RDD-2007 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
rifamycin CR - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
RP-182 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Small Molecule for Colitis - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Small Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Synthetic Peptides to Inhibit Panx1 for Colitis and Inflammatory Bowel Disease - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Vaccine to Target IL12 and IL23 for Colitis - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
Vaccine to Target IL23 for Colitis - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
ZK-216348 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
Colitis - Dormant Projects 96
Colitis - Discontinued Products 99
Colitis - Product Development Milestones 100
Featured News & Press Releases 100
Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX 100
Jul 11, 2013: Mylan Confirms First-to-File Patent Challenge Relating to CANASA 100
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 101
Disclaimer 102
List of Tables
Number of Products under Development for Colitis, H2 2016 11
Number of Products under Development for Colitis - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Investigation by Universities/Institutes, H2 2016 20
Colitis - Pipeline by Aerpio Therapeutics, Inc., H2 2016 21
Colitis - Pipeline by Akebia Therapeutics, Inc., H2 2016 22
Colitis - Pipeline by Amorepacific Corporation, H2 2016 23
Colitis - Pipeline by Bayer AG, H2 2016 24
Colitis - Pipeline by Bristol-Myers Squibb Company, H2 2016 25
Colitis - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2016 26
Colitis - Pipeline by Dr. Falk Pharma GmbH, H2 2016 27
Colitis - Pipeline by EA Pharma Co Ltd, H2 2016 28
Colitis - Pipeline by Euroscreen S.A., H2 2016 29
Colitis - Pipeline by Genfit SA, H2 2016 30
Colitis - Pipeline by Immuron Limited, H2 2016 31
Colitis - Pipeline by Innate Pharma S.A., H2 2016 32
Colitis - Pipeline by Peptinov SAS, H2 2016 33
Colitis - Pipeline by Pfizer Inc., H2 2016 34
Colitis - Pipeline by Prokarium Limited, H2 2016 35
Colitis - Pipeline by RDD Pharma Ltd., H2 2016 36
Colitis - Pipeline by Saniona AB, H2 2016 37
Colitis - Pipeline by Synovo GmbH, H2 2016 38
Assessment by Monotherapy Products, H2 2016 39
Number of Products by Stage and Target, H2 2016 41
Number of Products by Stage and Mechanism of Action, H2 2016 43
Number of Products by Stage and Route of Administration, H2 2016 45
Number of Products by Stage and Molecule Type, H2 2016 47
Colitis - Dormant Projects, H2 2016 96
Colitis - Dormant Projects (Contd..1), H2 2016 97
Colitis - Dormant Projects (Contd..2), H2 2016 98
Colitis - Discontinued Products, H2 2016 99
List of Figures
Number of Products under Development for Colitis, H2 2016 11
Number of Products under Development for Colitis - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Products, H2 2016 18
Assessment by Monotherapy Products, H2 2016 39
Number of Products by Top 10 Targets, H2 2016 40
Number of Products by Stage and Top 10 Targets, H2 2016 40
Number of Products by Top 10 Mechanism of Actions, H2 2016 42
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 42
Number of Products by Routes of Administration, H2 2016 44
Number of Products by Stage and Routes of Administration, H2 2016 44
Number of Products by Top 10 Molecule Types, H2 2016 46
Number of Products by Stage and Top 10 Molecule Types, H2 2016 46
